C1-INH and C3/C4 levels do not correlate with long-term danazole dosage and HAE-1 attack-free interval.
Schneider
L A
LA
Department of Dermatology and Allergology, University of Ulm, Maienweg 12, D-89081 Ulm, Germany. lars-alexander.schneider@medizin.uni-ulm.de
Maetzke
J
J
Staib
G
G
Scharffetter-Kochanek
K
K
D000799:Angioedema / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000032:analysis; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis*; D003613:Danazol / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; D003174:Complement C1 Inactivator Proteins; D003176:Complement C3; D003181:Complement C4; D003165:Complement System Proteins; D003613:Danazol